Introduction
Invasive meningococcal disease (IMD) has been a notifiable disease in Canada since 1924 (1) . It is caused by Neisseria meningitidis, which normally resides in the upper respiratory tract of healthy carriers. For reasons not completely understood, N. meningitidis may invade the blood stream and cause serious systemic infection leading to meningitis, septicemia, septic arthritis, bacteremic pneumonia and pericarditis (2) . Initial clinical presentation of IMD can be nonspecific but it may progress rapidly, leading to septic shock. The disease has an average case-fatality rate of 10% (3) . The strains causing IMD have been described as "shifting sands", with unique strains emerging with the potential to spread regionally and internationally. For example, MenA of subgroup III caused epidemics in China in the 1960s and subsequently spread to Russia and then globally (6) . ET-5 MenB caused an intercontinental outbreak with a wide geographic spread that lasted for over a decade (7) . The ET-15 MenC clone first emerged in Canada in the mid-1980s and led to worldwide dissemination, which ultimately led to the introduction of MenC conjugate vaccine programs in many countries. Other notable MenB clones that have caused epidemics include cluster A4 and lineage 3 (5).
The first report of MenW causing a major outbreak or epidemic occurred in 2000; this outbreak started in Saudi Arabia during the Hajj and involved more than 400 cases. The strain was characterized as ST-11 clonal complex (8) . With pilgrims returning to their countries in Africa, Asia, Europe, North America and South America, this strain was disseminated globally. The gradual increase in MenW disease in recent years was first reported in sub-Saharan Africa (9) and South America (10, 11) . Since 2010, other countries have reported an increase in IMD caused by . 
Methods
Provincial public health laboratories receive case isolates from hospitals and clinical diagnostic laboratories for identification and serogroup typing. As part of the enhanced surveillance program on IMD, all provinces and territories in Canada routinely submit all their invasive N. meningitidis isolates from culture-confirmed cases to the National Microbiology Laboratory (NML) for serogroup confirmation and additional strain characterization (17) . This study included all N. meningitidis isolates obtained from culture-confirmed IMD cases submitted to the NML between 2009 and 2016.
Typing of meningococci
At the NML, serogrouping is done by slide agglutination using rabbit anti-grouping antisera produced in-house and/or polymerase chain reaction (PCR) (18) . Serotyping and serosubtyping is done by whole-cell enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies (19) . PorA genotyping and multilocus sequence typing were conducted according to previously described standard methods (20, 21) .
Geographic distribution, source and patient characteristics
Based on the requisition information provided by the provincial public health laboratories, the NML collects and analyzes information on the geographic origin of the specimens, the source (e.g. blood, cerebral spinal, pericardial or intra-articular fluid) and the age and sex of patients from whom the specimens were drawn.
Results

Trends in MenW meningococcal disease
In Canada, between 2009 and 2016, a total of 888 N. meningitidis isolates were recovered from individual IMD cases and sent to the NML. Of these, 63 were grouped as MenW. The percentage of MenW isolates varied by year from a low of 2.7% in 2012 to a high of 18.8% in 2016 ( Table 1) , for an average percentage of 7.1%.
Changes in clonal complex
The increase in the number of MenW isolates from IMD cases coincided with the identification of the ST-11 (ET-37) CC (Figure 1) . From 2009 to 2013, 91% (32 out of 35) MenW isolates were typed as the traditional ST-22 clonal complexes whereas from 2014 to 2016, only 25% (7 out of 28) MenW isolates belonged to this clonal complex. Over this same period, the emerging ST-11 clonal complex increased from 3% (1 out of 35 isolates) to 75% (21 out of 28 isolates). 
Antigenic and genetic characterization
Geographic, demographic and source data
MenW isolates of the ST-11 CC were found in British Columbia (n = 5), Alberta (n = 3), Manitoba (n = 2), Ontario (n = 8) and Quebec (n = 4). The sex and age distribution of cases due to ST-22 and ST-11 CCs are shown in 
